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cebo. The endpoint change in the RQLQ was stratified
by self-assessed change to determine the NNT. This re-
sulted in a NNT of 7.9 for fexofenadine, 63.5 for lorata-
dine and 9.2 for fexofenadine versus loratadine. Thus,
between 7–8 patients require treatment with fexofena-
dine for a patient to have a clinically meaningful im-
provement in quality of life while between 63–64 patients
need to be treated with loratadine in order for one pa-
tient to obtain a significant improvement. Additional
stratifications were examined to assess the effects of im-
portant differences on the NNT. Single digit NNT values,
as seen with fexofenadine, strongly support the clinical
relevance of the drug for improving patient quality of
life. CONCLUSIONS: The NNT approach represents an
understandable approach to presenting quality of life
data that may be more meaningful to practicing physi-
cians.
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The American Urology Association has developed a 7-
item instrument I-PSS to measure the signs and symptoms
of the disease process of BPH. The instrument was vali-
dated for a one-month and later for a weekly recall. Early
and faster relief of symptoms are extremely important to
patients. Therefore, we validated I-PSS for as early as 2 to
5 day response. OBJECTIVE: To test the reliability and
validity of I-PSS administered between day two to five
post-treatment. METHODS: I-PSS was administered at
baseline and at day 2–5 after treatment as part of a double-
blind study with 674 symptomatic BPH subjects. The pa-
tients were also administered a single item global question
about their urinary condition. The test-retest reliability of
the 2–5 day version was evaluated with intra-class correla-
tion coefficient (ICC) between the two assessments. Inter-
nal consistency was computed with Cronbach’s . Guyatt’s
responsiveness statistics was estimated. Factor content of
day 2 to 5 I-PSS was examined. The ability of I-PSS
scores at days 2–5 to discriminate between improved and
unimproved subjects was tested with receiver’s operating




Improved 0.6089 0.0915 0.0279
Unchanged 0.1691 0.0254 0.0077
Deteriorated 0.0580 0.0087 0.0027
erage measure of ICC was found to be 0.7414. Cron-
bach’s  was estimated to be 0.8093 (Barry et al 1995 re-
ported 0.74 for ICC and 0.67 for Cronbach’s  for one-
week I-PSS). The Guyatt’s responsiveness statistic was
found to be 1.04 compared to 0.82 for a one-week
version. Factor analysis revealed only one underlying fac-
tor (urinary symptoms) with an eigenvalue greater than
one. The areas under ROC curve was 0.7635 (0.74 re-
ported for a one-week version). CONCLUSIONS: The
results conclude that I-PSS can be used to evaluate days
2–5 symptoms for BPH.
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OBJECTIVES: The research objective was to develop a
flexible Bayesian statistical framework for cost-effective-
ness analysis using data from a clinical trial, and to illus-
trate the methodology in practical case studies. METH-
ODS: The general methods of Bayesian statistical theory
are used to develop the framework. For computation of
results in case studies, simulation-based methods are
used, including Markov chain Monte Carlo. RESULTS:
A general framework is established, in which individual
patient data arising in a clinical trial may be modeled us-
ing any appropriate probability models. Within the model,
the true patient mean efficacy and true patient mean cost
are represented as functions of the model parameters.
Cost-effectiveness decisions are then based on inference
about these true mean parameters for each of the two
treatments under comparison in the trial. It is argued that
appropriate decision indicators are whether the expected
net benefit is positive, or the probability that net benefit
is positive, with net benefit defined with reference to a
specific threshold unit cost. When a range of unit costs
must be considered, the relevant indicators are the break-
even unit cost for expected net benefit, or the C/E accept-
ability curve (CEAC). Inference about these indicators is
determined within the Bayesian statistical paradigm. Ex-
amples and case studies are presented illustrating the
method with efficacy outcomes that are continuous, bi-
nary, ordinal or time-to-event, and with costs modeled as
distributed normally, lognormally or nonparametrically.
CONCLUSIONS: The Bayesian framework is demonstrated
to be both a flexible and powerful tool for cost-effectiveness
analysis from clinical trial data.
